2 years ago

Laverock Therapeutics Secures £13.5 Million Seed Funding for Gene Silencing Platform

  • Laverock Therapeutics, a UK-based provider of a gene silencing platform, has raised £13.5 million in Seed funding led by Calculus Capital

  • The funding will be used to further develop its GEiGS technology and progress its programs in regenerative medicine and immuno-oncology

  • Laverock is developing a gene silencing platform for the creation of programmable advanced human therapeutic applications

  • GEiGS uses universal gene editing tools to minimally edit non-coding genes and redirect their silencing activity (RNAi) towards a new target gene.

      • ProblemHealthcare

      "Current gene silencing approaches lack the ability to be targeted to specific cell types or conditions, limiting their effectiveness and potential side effects."

      Solution

      "Laverock Therapeutics' GEiGS platform uses universal gene editing tools to minimally edit non-coding genes and redirect their silencing activity (RNAi) towards a new target gene. This approach allows for cell type- or condition-specific gene silencing, improving efficacy and reducing off-target effects."

      Covered on